|
1
|
Angulo P: Nonalcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pagano G, Pacini G, Musso G, Gambino R,
Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P and
Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and
metabolic syndrome: further evidence for an etiologic association.
Hepatology. 35:367–372. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petersen KF, Dufour S, Befroy D, Lehrke M,
Hendler RE and Shulman GI: Reversal of nonalcoholic hepatic
steatosis, hepatic insulin resistance, and hyperglycemia by
moderate weight reduction in patients with type 2 diabetes.
Diabetes. 54:603–608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scorletti E, Calder PC and Byrne CD:
Non-alcoholic fatty liver disease and cardiovascular risk:
metabolic aspects and novel treatments. Endocrine. 40:332–343.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Angrand PO, Coffinier C and Weiss MC:
Response of the phosphoenolpyruvate carboxykinase gene to
glucocorticoids depends on the integrity of the cAMP pathway. Cell
Growth Differ. 5:957–966. 1994.PubMed/NCBI
|
|
6
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Samuel VT, Petersen KF and Shulman GI:
Lipid-induced insulin resistance: unravelling the mechanism.
Lancet. 375:2267–2277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greenberg AS, Coleman RA, Kraemer FB,
McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H and Mashek DG: The
role of lipid droplets in metabolic disease in rodents and humans.
J Clin Invest. 121:2102–2110. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Evans RM, Barish GD and Wang YX: PPARs and
the complex journey to obesity. Nat Med. 10:355–361. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosen ED, Hsu CH, Wang X, Sakai S, Freeman
MW, Gonzalez FJ and Spiegelman BM: C/EBPalpha induces adipogenesis
through PPARgamma: a unified pathway. Genes Dev. 16:22–26. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ratziu V, Giral P, Jacqueminet S,
Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte
JM, Bernhardt C, Bruckert E, et al LIDO Study Group: Rosiglitazone
for nonalcoholic steatohepatitis: one-year results of the
randomized placebo-controlled Fatty Liver Improvement with
Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 135:100–110.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ratziu V, Charlotte F, Bernhardt C, Giral
P, Halbron M, Lenaour G, Hartmann-Heurtier A and Bruckert E:
Long-term efficacy of rosiglitazone in nonalcoholic
steato-hepatitis: results of the fatty liver improvement by
rosiglitazone therapy (FLIRT 2) extension trial. Hepatology.
51:445–453. 2010. View Article : Google Scholar
|
|
13
|
Pettinelli P and Videla LA: Up-regulation
of PPAR-gamma mRNA expression in the liver of obese patients: an
additional reinforcing lipogenic mechanism to SREBP-1c induction. J
Clin Endocrinol Metab. 96:1424–1430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edvardsson U, Ljungberg A and Oscarsson J:
Insulin and oleic acid increase PPARgamma2 expression in cultured
mouse hepatocytes. Biochem Biophys Res Commun. 340:111–117. 2006.
View Article : Google Scholar
|
|
15
|
Matsusue K, Kusakabe T, Noguchi T,
Takiguchi S, Suzuki T, Yamano S and Gonzalez FJ: Hepatic steatosis
in leptin-deficient mice is promoted by the PPARgamma target gene
Fsp27. Cell Metab. 7:302–311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dubois RN, Abramson SB, Crofford L, Gupta
RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in
biology and disease. FASEB J. 12:1063–1073. 1998.PubMed/NCBI
|
|
17
|
Murakami M, Matsumoto R, Austen KF and Arm
JP: Prostaglandin endoperoxide synthase-1 and -2 couple to
different transmembrane stimuli to generate prostaglandin D2 in
mouse bone marrow-derived mast cells. J Biol Chem. 269:22269–22275.
1994.PubMed/NCBI
|
|
18
|
Anderson GD, Hauser SD, McGarity KL,
Bremer ME, Isakson PC and Gregory SA: Selective inhibition of
cyclooxygenase (COX)-2 reverses inflammation and expression of
COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest.
97:2672–2679. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ricciotti E and FitzGerald GA:
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol.
31:986–1000. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen
CH and Shih KC: COX-2-mediated inflammation in fat is crucial for
obesity-linked insulin resistance and fatty liver. Obesity (Silver
Spring). 17:1150–1157. 2009.
|
|
21
|
Muzio G, Trombetta A, Maggiora M,
Martinasso G, Vasiliou V, Lassen N and Canuto RA: Arachidonic acid
suppresses growth of human lung tumor A549 cells through
down-regulation of ALDH3A1 expression. Free Radic Biol Med.
40:1929–1938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Avis I, Martínez A, Tauler J, Zudaire E,
Mayburd A, Abu-Ghazaleh R, Ondrey F and Mulshine JL: Inhibitors of
the arachidonic acid pathway and peroxisome proliferator-activated
receptor ligands have superadditive effects on lung cancer growth
inhibition. Cancer Res. 65:4181–4190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schadinger SE, Bucher NL, Schreiber BM and
Farmer SR: PPARgamma2 regulates lipogenesis and lipid accumulation
in steatotic hepatocytes. Am J Physiol Endocrinol Metab.
288:E1195–E1205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gavrilova O, Haluzik M, Matsusue K, Cutson
JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ and
Reitman ML: Liver peroxisome proliferator-activated receptor gamma
contributes to hepatic steatosis, triglyceride clearance, and
regulation of body fat mass. J Biol Chem. 278:34268–34276. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Forman BM, Tontonoz P, Chen J, Brun RP,
Spiegelman BM and Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2
is a ligand for the adipocyte determination factor PPAR gamma.
Cell. 83:803–812. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maggiora M, Oraldi M, Muzio G and Canuto
RA: Involvement of PPARα and PPARγ in apoptosis and proliferation
of human hepatocarcinoma HepG2 cells. Cell Biochem Funct.
28:571–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lessard SJ, Rivas DA, Chen ZP, Bonen A,
Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB III and Hawley JA:
Tissue-specific effects of rosiglitazone and exercise in the
treatment of lipid-induced insulin resistance. Diabetes.
56:1856–1864. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Djaouti L, Jourdan T, Demizieux L, Chevrot
M, Gresti J, Vergès B and Degrace P: Different effects of
pioglitazone and rosiglitazone on lipid metabolism in mouse
cultured liver explants. Diabetes Metab Res Rev. 26:297–305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morán-Salvador E, López-Parra M,
García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A,
López-Vicario C, Barak Y, Arroyo V and Clària J: Role for PPARγ in
obesity-induced hepatic steatosis as determined by hepatocyte and
macrophage-specific conditional knockouts. FASEB J. 25:2538–2550.
2011. View Article : Google Scholar
|
|
30
|
Sugii S, Olson P, Sears DD, Saberi M,
Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, et al:
PPARgamma activation in adipocytes is sufficient for systemic
insulin sensitization. Proc Natl Acad Sci USA. 106:22504–22509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hevener AL, He W, Barak Y, Le J,
Bandyopadhyay G, Olson P, Wilkes J, Evans RM and Olefsky J:
Muscle-specific Pparg deletion causes insulin resistance. Nat Med.
9:1491–1497. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Norris AW, Chen L, Fisher SJ, Szanto I,
Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ and Gonzalez
FJ: Muscle-specific PPARgamma-deficient mice develop increased
adiposity and insulin resistance but respond to thiazolidinediones.
J Clin Invest. 112:608–618. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Puigserver P, Rhee J, Donovan J, Walkey
CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D
and Spiegelman BM: Insulin-regulated hepatic gluconeogenesis
through FOXO1-PGC-1alpha interaction. Nature. 423:550–555. 2003.
View Article : Google Scholar
|
|
34
|
Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S,
Befroy D, Romanelli AJ and Shulman GI: Mechanism of hepatic insulin
resistance in non-alcoholic fatty liver disease. J Biol Chem.
279:32345–32353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samuel VT, Liu ZX, Wang A, Beddow SA,
Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S and Shulman GI:
Inhibition of protein kinase Cepsilon prevents hepatic insulin
resistance in nonalcoholic fatty liver disease. J Clin Invest.
117:739–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deushi M, Nomura M, Kawakami A, Haraguchi
M, Ito M, Okazaki M, Ishii H and Yoshida M: Ezetimibe improves
liver steatosis and insulin resistance in obese rat model of
metabolic syndrome. FEBS Lett. 581:5664–5670. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nomura M, Ishii H, Kawakami A and Yoshida
M: Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic
insulin resistance. Am J Physiol Endocrinol Metab. 297:E1030–E1038.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Henkel J, Neuschäfer-Rube F,
Pathe-Neuschäfer-Rube A and Püschel GP: Aggravation by
prostaglandin E2 of interleukin-6-dependent insulin resistance in
hepatocytes. Hepatology. 50:781–790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen J, Liu D, Bai Q, Song J, Guan J, Gao
J, Liu B, Ma X and Du Y: Celecoxib attenuates liver steatosis and
inflammation in non-alcoholic steatohepatitis induced by high-fat
diet in rats. Mol Med Rep. 4:811–816. 2011.PubMed/NCBI
|
|
40
|
Boden G, She P, Mozzoli M, Cheung P,
Gumireddy K, Reddy P, Xiang X, Luo Z and Ruderman N: Free fatty
acids produce insulin resistance and activate the proinflammatory
nuclear factor-kappaB pathway in rat liver. Diabetes. 54:3458–3465.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tosello-Trampont AC, Landes SG, Nguyen V,
Novobrantseva TI and Hahn YS: Kupffer cells trigger nonalcoholic
steatohepatitis development in diet-induced mouse model through
tumor necrosis factor-α production. J Biol Chem. 287:40161–40172.
2012. View Article : Google Scholar : PubMed/NCBI
|
